- Markets
- Healthcare
- BPLPHARMA
BPLPHARMA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Bharat Parenterals Secures $27 Mln Order For Pharmaceutical Products
Jan 28 (Reuters) - Bharat Parenterals Ltd BATP.BO:
SECURES $27 MILLION ORDER FOR PHARMACEUTICAL PRODUCTS
Source text: ID:nBSE7k7CV
Further company coverage: BATP.BO
(([email protected];;))
Jan 28 (Reuters) - Bharat Parenterals Ltd BATP.BO:
SECURES $27 MILLION ORDER FOR PHARMACEUTICAL PRODUCTS
Source text: ID:nBSE7k7CV
Further company coverage: BATP.BO
(([email protected];;))
Syschem India jumps after fund raise plan
** Shares of Syschem (India) SYCH.BO rise as much as 15.6% to 55 rupees, hitting their highest since May 2024
** Active pharmaceutical ingredient maker to consider raising funds via issue of equity or warrants on Dec. 24
** SYCH eyes best day since Jan. 2024; on track to snap two-day losing run
** Stock up ~8% so far this year, on track for fifth straight year of gains
** Peer Bharat Parenterals BATP.BO surged ~102% YTD
(Reporting by Dimpal Gulwani in Bengaluru)
** Shares of Syschem (India) SYCH.BO rise as much as 15.6% to 55 rupees, hitting their highest since May 2024
** Active pharmaceutical ingredient maker to consider raising funds via issue of equity or warrants on Dec. 24
** SYCH eyes best day since Jan. 2024; on track to snap two-day losing run
** Stock up ~8% so far this year, on track for fifth straight year of gains
** Peer Bharat Parenterals BATP.BO surged ~102% YTD
(Reporting by Dimpal Gulwani in Bengaluru)
Bharat Parenterals Says Unit Out-Licenses Two Molecules To Generic Pharma MNCs
Nov 21 (Reuters) - Bharat Parenterals Ltd BATP.BO:
UNIT OUT-LICENSES TWO MOLECULES TO GENERIC PHARMA MNCS
Source text: ID:nBSEbFrQh2
Further company coverage: BATP.BO
(([email protected];;))
Nov 21 (Reuters) - Bharat Parenterals Ltd BATP.BO:
UNIT OUT-LICENSES TWO MOLECULES TO GENERIC PHARMA MNCS
Source text: ID:nBSEbFrQh2
Further company coverage: BATP.BO
(([email protected];;))
Bharat Parenterals Acquires Additional Stake In Innoxel Lifesciences
June 24 (Reuters) - Bharat Parenterals Ltd BATP.BO:
ACQUISITION OF ADDITIONAL STAKE IN INNOXEL LIFESCIENCES
ACQUISITION OF VARENYAM HEALTHCARE
ACQUISITION OF VARENYAM BIO-LIFESCIENCES
Source text for Eikon: ID:nBSE5Wt3cz
Further company coverage: BATP.BO
(([email protected];;))
June 24 (Reuters) - Bharat Parenterals Ltd BATP.BO:
ACQUISITION OF ADDITIONAL STAKE IN INNOXEL LIFESCIENCES
ACQUISITION OF VARENYAM HEALTHCARE
ACQUISITION OF VARENYAM BIO-LIFESCIENCES
Source text for Eikon: ID:nBSE5Wt3cz
Further company coverage: BATP.BO
(([email protected];;))
Bharat Parenterals Approved Raising Of Further Capital
June 10 (Reuters) - Bharat Parenterals Ltd BATP.BO:
APPROVED RAISING OF FURTHER CAPITAL BY WAY OF ISSUE OF SHARES AT 1,465 RPEES PER SHARE
APPROVED RAISING FURTHER CAPITAL VIA PREFERENTIAL ISSUE OF EQUITY SHARES
Further company coverage: BATP.BO
(([email protected];))
June 10 (Reuters) - Bharat Parenterals Ltd BATP.BO:
APPROVED RAISING OF FURTHER CAPITAL BY WAY OF ISSUE OF SHARES AT 1,465 RPEES PER SHARE
APPROVED RAISING FURTHER CAPITAL VIA PREFERENTIAL ISSUE OF EQUITY SHARES
Further company coverage: BATP.BO
(([email protected];))
Bharat Parenterals To Consider And Evaluate Proposal For Issue Of Equity Shares On Preferential Basis
June 6 (Reuters) - Bharat Parenterals Ltd BATP.BO:
BHARAT PARENTERALS - TO CONSIDER AND EVALUATE PROPOSAL FOR ISSUE OF EQUITY SHARES ON PREFERENTIAL BASIS
Source text for Eikon: ID:nBSE1bFthn
Further company coverage: BATP.BO
(([email protected];))
June 6 (Reuters) - Bharat Parenterals Ltd BATP.BO:
BHARAT PARENTERALS - TO CONSIDER AND EVALUATE PROPOSAL FOR ISSUE OF EQUITY SHARES ON PREFERENTIAL BASIS
Source text for Eikon: ID:nBSE1bFthn
Further company coverage: BATP.BO
(([email protected];))
Bharat Parenterals Says Will Acquire Additional 10 Million Shares Of Unit Innoxel Lifesciences
June 5 (Reuters) - Bharat Parenterals Ltd BATP.BO:
BHARAT PARENTERALS LTD - CO WILL ACQUIRE ADDITIONAL 10 MILLION SHARES OF UNIT INNOXEL LIFESCIENCES
Source text for Eikon: ID:nBSE5yKtjz
Further company coverage: BATP.BO
(([email protected];))
June 5 (Reuters) - Bharat Parenterals Ltd BATP.BO:
BHARAT PARENTERALS LTD - CO WILL ACQUIRE ADDITIONAL 10 MILLION SHARES OF UNIT INNOXEL LIFESCIENCES
Source text for Eikon: ID:nBSE5yKtjz
Further company coverage: BATP.BO
(([email protected];))
Bharat Parenterals Approved Raising Of Further Capital
April 29 (Reuters) - Bharat Parenterals Ltd BATP.BO:
APPROVED RAISING OF FURTHER CAPITAL AGGREGATING TO 981.5 MILLION RUPEES
APPROVED RAISING OF FURTHER CAPITAL BY WAY OF ISSUE OF SHARES ON A PREFERENTIAL BASIS
Source text for Eikon: ID:nBSE87MKXz
Further company coverage: BATP.BO
(([email protected];;))
April 29 (Reuters) - Bharat Parenterals Ltd BATP.BO:
APPROVED RAISING OF FURTHER CAPITAL AGGREGATING TO 981.5 MILLION RUPEES
APPROVED RAISING OF FURTHER CAPITAL BY WAY OF ISSUE OF SHARES ON A PREFERENTIAL BASIS
Source text for Eikon: ID:nBSE87MKXz
Further company coverage: BATP.BO
(([email protected];;))
Events:
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Bharat Parenterals do?
Bharat Parenterals Limited specializes in manufacturing pharmaceutical formulations for domestic and international markets, aiming to become a leading company by providing high-quality products meeting customer and regulatory standards.
Who are the competitors of Bharat Parenterals?
Bharat Parenterals major competitors are Sakar Healthcare, Prevest Denpro, Medicamen Biotech, Kilitch Drugs(India), Ind-Swift Lab., Albert David, Medico Remedies. Market Cap of Bharat Parenterals is ₹689 Crs. While the median market cap of its peers are ₹565 Crs.
Is Bharat Parenterals financially stable compared to its competitors?
Bharat Parenterals seems to be less financially stable compared to its competitors. Altman Z score of Bharat Parenterals is 2.59 and is ranked 8 out of its 8 competitors.
Does Bharat Parenterals pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Bharat Parenterals latest dividend payout ratio is 4.01% and 3yr average dividend payout ratio is 3.32%
How has Bharat Parenterals allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Bharat Parenterals balance sheet?
Balance sheet of Bharat Parenterals is moderately strong.
Is the profitablity of Bharat Parenterals improving?
No, profit is decreasing. The profit of Bharat Parenterals is -₹36.79 Crs for TTM, ₹14.52 Crs for Mar 2024 and ₹16.4 Crs for Mar 2023.
Is the debt of Bharat Parenterals increasing or decreasing?
The debt of Bharat Parenterals is decreasing. Latest debt of Bharat Parenterals is ₹90.19 Crs as of Sep-24. This is less than Mar-24 when it was ₹133 Crs.
Is Bharat Parenterals stock expensive?
Bharat Parenterals is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Bharat Parenterals is 0.0, while 3 year average PE is 18.65. Also latest EV/EBITDA of Bharat Parenterals is 526 while 3yr average is 54.91.
Has the share price of Bharat Parenterals grown faster than its competition?
Bharat Parenterals has given better returns compared to its competitors. Bharat Parenterals has grown at ~38.37% over the last 3yrs while peers have grown at a median rate of 13.95%
Is the promoter bullish about Bharat Parenterals?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Bharat Parenterals is 67.2% and last quarter promoter holding is 67.2%.
Are mutual funds buying/selling Bharat Parenterals?
There is Insufficient data to gauge this.